Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2002

View Archived Issues

Johnson & Johnson to acquire all assets of Tibotec-Virco

New controlled release oral morphine product receives regulatory approval in Canada

Nobex and Pharmacia collaborate on oral protein drug delivery

Amrad ceases further development of emfilermin for chemotherapy-induced peripheral neuropathy

Aventis and Eisai to copromote Actonel in Japan

Phase I clinical trials of Genexol-PM commence in patients with refractory cancer

Calcium-sensing receptor modulators described in a recent CNRS patent

New antitumor compounds from marine sponge synthesized at the University of Barcelona

Ortho-McNeil claims new series of neuroprotective derivatives

Steroid derivatives useful for treating a number of neurodegenerative diseases identified at Kyorin

Angiotensin II antagonists jointly reported by Asahi Glass and Mitsubishi Pharma

ProusNet Channel 1 presents Orphan G-Protein Coupled Receptors

European Commission grants marketing approval for Arixtra

Dynepo receives E.U. approval for anemia of renal failure

Cellegy commences phase II/III trial of Tostrelle for treatment of FSD

ISTA reports preliminary phase III results for Vitrase

Keiten marketing rights transfer from Chugai to Fujisawa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...